FAES

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

Retrieved on: 
Monday, March 25, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Diagnosis, Neurology, Socialization, Communication, Disease, Seizure, Patient, Fenfluramine, University, OLE, Behavior, Cognition, Therapy, Natural history, FAES, Dravet syndrome, Movement, Pediatrics, Food, Medicine, Pharmaceutical industry

Data from these studies showed clinically meaningful effects, including substantial and durable reductions in convulsive seizure frequency and improvements in multiple measures of cognition and behavior that support the potential for disease modification.

Key Points: 
  • Data from these studies showed clinically meaningful effects, including substantial and durable reductions in convulsive seizure frequency and improvements in multiple measures of cognition and behavior that support the potential for disease modification.
  • These improvements were observed among a highly refractory group of patients who were already taking the best available anti-seizure medicines.
  • Today, the Company also announced clearance from the U.S. Food and Drug Administration (FDA) that allows patients to receive three doses of 70mg followed by continued dosing at 45mg.
  • “STK-001 is the first medicine in development to demonstrate substantial and durable reductions in seizure frequency and improvements in multiple measures of cognition and behavior.

Silicon Motion Announces New Organizational Structure to Support Continued Global Business Growth

Retrieved on: 
Monday, December 11, 2023
FAES, Synaptics, Marketing, OEM, GM, Silicon Motion, SMI USA, UltraSPARC, Wireless, Wi-Fi, SSD, Data, SMI, Spansion, IDT, Client, Intel, SIMO, Sun Microsystems, ESDI, Growth, Small Business Saturday, Silicon, Broadcom Inc., CAS, Motion, Senior, Management

TAIPEI, Taiwan and MILPITAS, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Silicon Motion Technology Corporation (NasdaqGS: SIMO) (“Silicon Motion,” the “Company” or “we”), a global leader in designing and marketing NAND flash controllers for solid-state storage devices, today, announced a new organizational structure and leadership team appointments to support the Company’s continued global business growth.

Key Points: 
  • TAIPEI, Taiwan and MILPITAS, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Silicon Motion Technology Corporation (NasdaqGS: SIMO) (“Silicon Motion,” the “Company” or “we”), a global leader in designing and marketing NAND flash controllers for solid-state storage devices, today, announced a new organizational structure and leadership team appointments to support the Company’s continued global business growth.
  • The Enterprise Storage & Display Interface Solution (“ESDI”) Business Unit will encompass the Company’s enterprise SSD controllers and display interface products.
  • As part of the new organizational structure, Silicon Motion has created the following leadership roles:
    Nelson S. Duann, currently Silicon Motion’s Senior Vice President of Marketing and R&D, has been appointed as a Senior Vice President of the CAS business unit.
  • Alex Chou joins Silicon Motion as a Senior Vice President to lead the ESDI business unit.

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting

Retrieved on: 
Friday, December 1, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Dravet syndrome, Brain, American Epilepsy Society, Annual general meeting, Behavior, Pediatrics, Therapy, FAES, Language, Disease, Patient, OLE, Movement, Disability studies, Seizure, Cognition, University, Speech, AES, Pharmaceutical industry, Medical imaging

Together, these data support the company’s continued progress to develop STK-001 as the first disease-modifying medicine for the treatment of Dravet syndrome.

Key Points: 
  • Together, these data support the company’s continued progress to develop STK-001 as the first disease-modifying medicine for the treatment of Dravet syndrome.
  • “The substantial and sustained reductions in seizure frequency and improvements in cognition and behavior observed in our STK-001 clinical studies give us confidence that we are addressing the root cause of Dravet syndrome.
  • Gaps in neurodevelopment continued to widen throughout the study among patients with Dravet syndrome compared to their age-matched neurotypical peers.
  • All presentations are available for download on the Stoke Therapeutics website under the Investors & News tab.

Children’s Hospital Los Angeles Names Sucheta Joshi, MD, MS, FAAP, FAES as Incoming Medical Director of Comprehensive Epilepsy Program

Retrieved on: 
Thursday, June 29, 2023
Health, Hospitals, Epilepsy, Seth, Telehealth, Bachelor, University of Mumbai, University, MBBS, National Association of Epilepsy Centers, Bachelor of Medicine, Bachelor of Surgery, CHLA, Policy, Advisory Committee, Pediatrics (journal), King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Service, American Academy, Multimedia, AAP, Research, Neurology, Montreal Neurological Institute and Hospital, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States, Stanford University School of Medicine, University of Michigan School of Dentistry, Michigan Medicine, Pediatric Neurology, Public health, Committee, Medical director, Division, Children's Hospital Los Angeles, FAES, University of Michigan School of Public Health, National Association, Nursing, Pharmaceutical industry, Pediatrics, FAAP, MD, Medicine

View the full release here: https://www.businesswire.com/news/home/20230629162494/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230629162494/en/
    Sucheta Joshi, MD, MS, FAAP, FAES, has been named as incoming Medical Director of the Neurological Institute Comprehensive Epilepsy Program at Children’s Hospital Los Angeles (CHLA).
  • She most recently has served as Service Chief of Pediatric Neurology and Medical Director of Pediatric Epilepsy at Michigan Medicine, the academic medical center of the University of Michigan, where she launched a complex epilepsy clinical program and an inpatient pediatric epilepsy service.
  • In her new role, Dr. Joshi will lead and expand the Comprehensive Epilepsy Program at CHLA and will grow programs such as telehealth, precision health trials, adult transition, team-based clinics and surgical epilepsy.
  • Joshi’s leadership will help us reach the full potential of our Comprehensive Epilepsy Program.

Quectel Wireless Solutions to Showcase Its Advanced IoT Products and Services at ElectroneX Event in Melbourne

Retrieved on: 
Wednesday, May 10, 2023
Technology, Mobile, Wireless, Semiconductor, Satellite, Other Technology, Software, Internet, Hardware, IOT (Internet of Things), IEEE 802.11ah, AT&T, CE, Communication, Wi-Fi, KC, Qualcomm, Reduction, Combo, Senior, FCC, Exhibition, AT, GNSS, Agriculture, RCM, IC, Certification, IEEE, ORBCOMM, ANATEL, Mining, Redcap, Bluetooth, Verizon Communications, University, ADAS, Transport, FAES, T-Mobile, TELUS, Renewable energy, Mobile phone, Internet of things, Vodafone

Quectel Wireless Solutions, a global IoT solutions provider, announces its participation in this year's ElectroneX event in Melbourne, Australia, where it will showcase some of its world-class products and services designed to help customers build a smarter world.

Key Points: 
  • Quectel Wireless Solutions, a global IoT solutions provider, announces its participation in this year's ElectroneX event in Melbourne, Australia, where it will showcase some of its world-class products and services designed to help customers build a smarter world.
  • "We are excited to be showcasing some of our latest IoT products and services at ElectroneX," said Michael Wallon, Senior Vice President of APAC and ANZ Sales, Quectel Wireless Solutions.
  • "Quectel has launched a number of new IoT products and services which demonstrates our commitment to delivering innovative solutions that meet the unique needs of our customers."
  • With its industry-leading products, Quectel is committed to delivering high-performance, reliable, and cost-effective solutions to meet the ever-evolving needs of the IoT market.

Latest XCOPRI® (cenobamate tablets) CV Post-hoc Analysis Presented at the 75th American Academy of Neurology Annual Meeting

Retrieved on: 
Monday, April 17, 2023
Epilepsy, Seizure, Abstract, Maintenance, Medical Affairs Bureau, Central nervous system, CV, ASMS, AAN, Grenfell Tower Inquiry Phase 2, Cenobamate, ASM, American Academy, MBA, CNS, Pharmacist, Death, MD, Patient, Annual general meeting, FAES, Mortality, American Academy of Neurology, FAAN, SUDEP, Pharmaceutical industry

The data includes post-hoc analyses on the rate of SUDEP and drug load in adults with partial-onset (focal) seizures taking XCOPRI® (cenobamate tablets) CV.

Key Points: 
  • The data includes post-hoc analyses on the rate of SUDEP and drug load in adults with partial-onset (focal) seizures taking XCOPRI® (cenobamate tablets) CV.
  • For people with epilepsy, the all-cause mortality rate is typically higher than the general population, with one factor being SUDEP.
  • For those with drug resistant epilepsy, the SUDEP rate increases to as high as 9.3 deaths per 1,000 person years.
  • All abstracts being presented at AAN, including the ten being presented by SK Life Science, can be found here and also at booth #2091.

Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Retrieved on: 
Wednesday, November 23, 2022
LGS, OLE, Patient, Children's Hospital Colorado, Fenfluramine, Communication, Death, Sleep, Seizure, UCB, GTCS, Valvular heart disease, FAES, Hypertensive emergency, Children's Hospital, MSCS, Associate professor, Generalized tonic–clonic seizure, Safety, Pharmaceutical industry, Euronext, Epilepsy

In that randomized trial, a total of 263 patients were assigned to receive either FINTEPLA 0.7 mg/kg/day (n=87) or FINTEPLA 0.2 mg/kg/day (n=89) or placebo (n=87).

Key Points: 
  • In that randomized trial, a total of 263 patients were assigned to receive either FINTEPLA 0.7 mg/kg/day (n=87) or FINTEPLA 0.2 mg/kg/day (n=89) or placebo (n=87).
  • A total of 247 eligible patients with LGS who completed that 14-week randomized Phase 3 clinical trial enrolled in the OLE study.
  • FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
  • If FINTEPLA is coadministered with strong CYP1A2 or CYP2D6 inhibitors, the maximum daily dosage of FINTEPLA is 20 mg.

BLT acquires the AMD-Xilinx Southeast training region

Retrieved on: 
Thursday, August 4, 2022
ACAP, Multimedia, Budget, FAES, SOC, ATP, Acquisition, View, Authorization, DE, BLT, FPGA, Mid-Atlantic Regional Spaceport, Student, Organization, Management, Video game console, Xilinx, MD

COLUMBIA, Md., Aug. 4, 2022 /PRNewswire/ -- BLT (formerly Bottom Line Technologies), a U.S.-owned and operated engineering design services firm and AMD-Xilinx Authorized Training Provider (ATP), announced yesterday that it has been named the exclusive in-person ATP for the AMD-Xilinx Southeast region. This expands BLT's territory from the Mid-Atlantic to nearly the entire Eastern seaboard.

Key Points: 
  • Engineering firm BLT is now the exclusive AMD-Xilinx Authorized Training Provider for the majority of the East Coast.
  • In additional to offering training online globally, BLT is the exclusive ATP for in-person training in the Mid-Atlantic (NY, PA, NJ, DE, MD, DC, VA, WV, KY) and now the Southeast (AL, FL, GA, MS, NC, SC, TN).
  • BLT earned the Southeast region with their recognized achievements in their existing markets.
  • About BLT: Founded in 1989 by one of Xilinx's original FAEs, BLT has set the standard for Xilinx training for over 25 years.

Duck Delivery: Young sickle cell disease patients at Children's Regional Hospital at Cooper in Camden, NJ receive award-winning social robot thanks to new collaboration with Aflac

Retrieved on: 
Friday, April 29, 2022
People, Women's Choice Awards, PRI, Trauma, Cooper University Hospital, Duck, Principles for Responsible Investment, SXSW, ESG, Sickle cell disease, American Chestnut Cooperators Foundation, Regional hospital, NYSE, Rowan University, Invention, FAES, Ethisphere Institute, Time, Pediatrics, St. Louis Fed Financial Stress Index, MD Anderson Cancer Center, CES, Patient, Education, Degenerative disease, Fortune, Cooper Medical School of Rowan University, Dow Jones, Cooper, MMM, JD, MD, FAAP, Hospital, Socially responsible investing, Multimedia, World, Social responsibility, Physician, Research, AFL, Cooper Foundation, 10th People's Choice Awards, Trauma center, Insurance, Trauma Center, Health, Principle, Medicine, Health insurance, Aflac, Sickle, Child

CAMDEN, N.J., April 29, 2022 /PRNewswire/ -- Today, several young patients being treated for sickle cell disease at Children's Regional Hospital at Cooper received a cuddly new companion specially designed to help them through their medical journey.  A duck delivery and unboxing event celebrated the new collaboration between Cooper and Aflac to provide a My Special Aflac Duck free of charge to all pediatric sickle cell patients ages 3 and above who are undergoing treatment.

Key Points: 
  • My Special Aflac Duck is a social robot that offers a sense of comfort, joy, and control to children undergoing cancer treatment and children living with sickle cell disease.
  • In early 2022, Aflac introduced a new-generation My Special Aflac Duck with features and play accessories designed specifically for sickle cell patients.
  • "Every year, nearly 200 children receive care through Children's Regional Hospital at Cooper's sickle cell program.
  • Children's Regional Hospital at Cooper Contact: Wendy A. Marano, 856.382.6463 or 856.904.1688 or [email protected]
    View original content to download multimedia: https://www.prnewswire.com/news-releases/duck-delivery-young-sickle-cell...

BLT introduces revolutionary changes to the Xilinx training market

Retrieved on: 
Monday, September 27, 2021
Sale, Multiprocessor system on a chip, View, FPGA, Silicon, Multimedia, Policy, Engineering, GOV, BLT, Socs, Alliance, FAES

BLT has announced that it is lowering prices on all its nationally offered online Xilinx training courses by two-thirds.

Key Points: 
  • BLT has announced that it is lowering prices on all its nationally offered online Xilinx training courses by two-thirds.
  • This strategic shift is not a sale or limited-time offer, BLT confirms: "This is the future of Xilinx training at BLT."
  • The content of the courses will not change, and BLT has announced additional plans to make online Xilinx training even more accessible.
  • BLT is a Xilinx Authorized Training Provider, Alliance Member and Xilinx Design Services provider.